Cargando…
A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease
To date, no drug has been proven to be neuroprotective or disease-modifying for Parkinson's disease (PD) in clinical trials. Here, we aimed to assess preclinical evidence of Ginsenosides-Rg1 (G-Rg1), a potential neuroprotectant, for experimental PD and its possible mechanisms. Eligible studies...
Autores principales: | Song, Liang, Xu, Meng-Bei, Zhou, Xiao-Li, Zhang, Dao-pei, Zhang, Shu-ling, Zheng, Guo-qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366755/ https://www.ncbi.nlm.nih.gov/pubmed/28386306 http://dx.doi.org/10.1155/2017/2163053 |
Ejemplares similares
-
Preclinical systematic review of ginsenoside Rg1 for cognitive impairment in Alzheimer’s disease
por: Liang, Hai-Yong, et al.
Publicado: (2021) -
Comment on “A Preclinical Systematic Review of Ginsenoside-Rg1 in Experimental Parkinson's Disease”
por: He, Yi-bo, et al.
Publicado: (2017) -
A systematic review and meta-analysis of Ginsenoside-Rg1 (G-Rg1) in experimental ischemic stroke
por: Xie, Cheng-long, et al.
Publicado: (2015) -
Effect of ginsenoside-Rg1 on experimental Parkinson's disease: A systematic review and meta-analysis of animal studies
por: He, Yi-Bo, et al.
Publicado: (2021) -
Comparative Pharmacokinetics of Ginsenoside Rg(3) and Ginsenoside Rh(2) after Oral Administration of Ginsenoside Rg(3) in Normal and Walker 256 Tumor-bearing Rats
por: Fan, He, et al.
Publicado: (2016)